SCHEMBL1723173

SCHEMBL1723173

O=C(C1=CCC(C(=O)c2ccc(F)cc2)(c2ccccc2)C=C1)c1ccc(F)cc1.O=C(c1ccc(F)cc1)c1cccc(C(=O)c2ccc(F)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CTSL P07711 2/20 0.36
CTSK P43235 1/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
HPGD P15428 4/20 0.36
LMNA P02545 3/20 0.36
ALPG P10696 1/20 0.36
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGA2 P17301 1/20 0.34
ALDH1A1 P00352 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
KDM4E B2RXH2 2/20 0.33
THRB P10828 1/20 0.33
PBRM1 Q86U86 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9814885 0.81 LMNA (0.35) SMN1; SMN2HPGDLMNAALPGITGB1
SCHEMBL5068796 0.77 LMNA (0.38) TDP1SMN1; SMN2HPGDLMNAALPG
SCHEMBL4448703 0.77 LMNA (0.38) TDP1SMN1; SMN2HPGDLMNAALPG
SCHEMBL9386897 0.76 LMNA (0.37) TDP1SMN1; SMN2HPGDLMNAALPG
SCHEMBL17950520 0.73 ATM (0.75) ATMTDP1L3MBTL1CTSLCTSK
SCHEMBL5880322 0.72 L3MBTL1 (0.47) ATMTDP1L3MBTL1SMN1; SMN2HPGD
SCHEMBL209624 0.70 ATM (0.67) ATMTDP1L3MBTL1CTSLCTSK
SCHEMBL2454243 0.70 ALDH1A1 (0.41) ATMTDP1L3MBTL1SMN1; SMN2HPGD
SCHEMBL993046 0.69 ALDH1A1 (0.43) ATMTDP1L3MBTL1SMN1; SMN2HPGD
SCHEMBL29034394 0.69 ALDH1A1 (0.39) ATMTDP1L3MBTL1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023692-B2 Method for the manufacture of poly(aryl ether ketone)s in the presence of sodium carbonate SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2018-07-17 US disclosed
US-20160145385-A1 METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S IN THE PRESENCE OF SODIUM CARBONATE SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2016-05-26 US disclosed
US-9175136-B2 Method for the manufacture of poly(aryl ether ketone)s in the presence of sodium carbonate SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2015-11-03 US disclosed
EP-2344565-B1 METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S IN THE PRESENCE OF SODIUM CARBONATE SOLVAY SPECIALTY POLYMERS USA (US) 2014-03-19 EP disclosed
US-20110213095-A1 Method for the manufacture of poly(aryl ether ketone)s in the presence of sodium carbonate SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2011-09-01 US disclosed
EP-2344565-A1 METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S IN THE PRESENCE OF SODIUM CARBONATE Solvay Advanced Polymers, L.L.C. (US) 2011-07-20 EP disclosed
EP-2342261-A1 IMPROVED METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S AND IMPROVED METHOD FOR PROVIDING A SODIUM CARBONATE SUITABLE FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S Solvay Advanced Polymers, L.L.C. (US) 2011-07-13 EP disclosed
WO-2010046484-A1 METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S IN THE PRESENCE OF SODIUM CARBONATE SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2010-04-29 WO disclosed
WO-2010046487-A1 IMPROVED METHOD FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S AND IMPROVED METHOD FOR PROVIDING A SODIUM CARBONATE SUITABLE FOR THE MANUFACTURE OF POLY(ARYL ETHER KETONE)S SOLVAY ADVANCED POLYMERS, L.L.C. (US) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023692-B2 Method for the manufacture of poly(aryl ether ketone)s in the presence of sodium carbonate PKM, KCNK10, KCNK9 ATM 1110/4885TDP1 3884/4885L3MBTL1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.